ABBV vs TSLA: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Tesla, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Tesla, Inc. · Consumer Cyclical
$387.51
-45.0% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+6.3%).
ABBV trades at a lower forward P/E
(83.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
TSLA |
| Current Price |
$197.69 |
$387.51 |
| Fair Value Estimate |
$210.22 |
$213.13 |
| Upside to Fair Value |
+6.3%
|
-45.0%
|
| Market Cap |
$349.7B |
$1,454.1B |
| Forward P/E |
83.3x
|
330.0x
|
| EV / EBITDA |
23.4x
|
122.9x
|
| Price / Sales |
5.7x
|
15.3x
|
| Price / FCF |
18.7x
|
233.8x
|
| Revenue Growth YoY |
+10.0%
|
-3.1%
|
| Gross Margin |
70.2%
|
18.0%
|
| Operating Margin |
26.7%
|
4.6%
|
| Return on Equity |
-361.6%
|
4.8%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
0.43%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Tesla, Inc. is a leading global manufacturer of electric vehicles, energy storage, and solar products, led by CEO Elon Musk since 2008. The company has a mixed business quality profile with a strong brand and innovation leadership but faces significant challenges including declining automotive revenue, which fell nearly 10% year-over-year in 2025, and a 3.1% revenue decline in the most recent qua…
Accumulation Zones
| Metric |
ABBV |
TSLA |
| Zone Low |
$157.66 |
$159.85 |
| Zone High |
$178.69 |
$181.16 |
| In Buy Zone? |
No
|
No
|